脊髄筋縮における併用療法:体系的なレビュー
Maryam Bemanalizadeh1,2, Leida Heidary3, Mohammad Sedigh Dakkali4
1Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.
European journal of pediatrics
|August 29, 2025
まとめ
nusinersen,onasemnogene abeparvovec- xioi,risdiplamを併用した治療法は,脊髄筋縮 (SMA) の治療において有望であることが示されています. 一般的に短期的には安全ですが,長期的な有効性や最適な配列化はさらなる調査が必要です.
科学分野:
- 神経学
- 遺伝学
- 薬理学について
背景:
- 脊髄筋縮 (SMA) の治療には3つの疾患修正療法がある.
- モノセラピーは,全てのSMA患者において,疾患の進行を止めることはできません.
- 併用療法 (アドオン/スイッチング) がSMAに登場しています.
研究 の 目的:
- SMAに対する組み合わせ治療の安全性,有効性,および臨床的適用を評価する.
- 単独治療よりも組み合わせ治療の潜在的な利点を評価する
- nusinersen,onasemnogene abeparvovec- xioi,risdiplamを含む二重および三重組み合わせの治療法を分析する.
主な方法:
- 主要なデータベース (PubMed,Scopus,Web of Science,ClinicalTrials.gov) から 2025年5月までの研究を体系的にレビューする.
- 二重または三重結合療法 (スイッチングまたはアドオン) に関する研究が含まれています.
- 人口統計,治療法,運動機能,有害事象に関するデータを抽出し,研究の質を評価した.
主要な成果:
- 19件の研究と6件の進行中の試験は,29人の患者を分析し,含める基準を満たした.
- ヌシネルセンやリスディプラムからオナセムノゲン・アベパルボベック・シオイに切り替えることが一般的でした.
- 併用治療は一般的によく許容され,一部の患者は早期介入で運動のマイルストーンと呼吸機能の改善を示した.
結論:
- SMAの併用治療は実行可能であり,特に単独治療で最適な反応が得られない患者には安全です.
- 現状の証拠は励ましいが 限られている.
- 確固たる長期試験は,真の有効性,最適な配列,およびより広範な影響を決定するために不可欠です.
さらに関連する動画
06:51Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
7.8K
07:02Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
Published on: May 11, 2018
13.7K
関連する概念動画
01:20Myasthenia Gravis: Overview and Treatment
3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
01:28Classification of Skeletal Muscle Relaxants
3.6K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
3.6K
01:31Skeletal Muscle Relaxants: Therapeutic Uses
1.2K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.2K
01:09Peripherally and Centrally Acting Muscle Relaxants: A Comparison
5.7K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
5.7K
01:28Disorders of the Skeletal Muscle
2.2K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.2K
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K